Aclaris Therapeutics (ACRS) Revenue (2017 - 2026)

Aclaris Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Revenue rose 37.18% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $8.4 million (down 52.94% YoY), while the FY2025 annual figure was $7.8 million, down 58.19% from the prior year.
• Revenue for Q1 2026 stood at $2.0 million, up from $1.3 million in the prior quarter.
• The five-year high for Revenue was $19.0 million in Q3 2022, with the low at $1.3 million in Q4 2025.
• The 5-year median for Revenue is $2.5 million (2023), against an average of $5.3 million.
• The sharpest annual moves came in 2022 and 2025: Revenue surged 1046.35% in 2022, then sank 85.94% in 2025.
• Aclaris Therapeutics' Revenue stood at $7.8 million in 2022, then jumped by 126.62% to $17.6 million in 2023, then plunged by 47.58% to $9.2 million in 2024, then tumbled by 85.94% to $1.3 million in 2025, then soared by 54.13% to $2.0 million in 2026.
• Business Quant data shows ACRS's Revenue at $2.0 million in Q1 2026, $1.3 million in Q4 2025, and $3.3 million in Q3 2025.